US3621094A - Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts - Google Patents
Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts Download PDFInfo
- Publication number
- US3621094A US3621094A US719234A US3621094DA US3621094A US 3621094 A US3621094 A US 3621094A US 719234 A US719234 A US 719234A US 3621094D A US3621094D A US 3621094DA US 3621094 A US3621094 A US 3621094A
- Authority
- US
- United States
- Prior art keywords
- antacid
- percent
- calcium
- gluconate
- magnesium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
Definitions
- This invention relates to new phannaceutically elegant antacid compositions. More specifically, this invention relates to aqueous pharmaceutical suspensions for oral use having antacid and antiulcer properties which contain a high concentration of antacid but which are also pharmaceutically stable and very palatable.
- Antacids are used for the treatment of gastric hyperacidity, dyspepsia and peptic ulcers. Antacids have played a major role in the clinical management of peptic ulcers and in appropriate doses to relieve the plain of this condition.
- a further disadvantage is that even commercially available antacid products have well recognized stability problems. One of these is their tendency to coagulate and clump upon standing. Further, the palatability of the prior art liquid antacids is very objectionable, i.e. they have a chalky and astringent taste. These problems are multiplied as the concentration of antacid increase.
- the preparations of this invention offer a much more concentrated form of antacid preparation than has been previously available. if such a concentration could be prepared in the vehicle of the prior art antacid preparation it would resemble a slightly damp chalk powder.
- This invention therefore provides a more convenient, stable and palatable liquid for antacid therapy.
- the preparation in accordance with this invention can contain as high as 50 percent antacid which represents more than a fivefold increase in concentration over the commercially available liquid antacid preparations.
- novel phamtaceutical preparations of this invention are unique in that they are not only much more concentrated than the commercially available antacid preparations but are also more pharmaceutically elegant. These antacid suspensions are more stable and have improved palatability being free of the gritty, astringent, chalky taste-which is so prevalent even with the previously known antacid compositions.
- novel pharmaceutical compositions of this invention are also unique in that they provide for improved concentrated liquid antacid formulations of the type which promptly neutralize gastric acidity and maintain this neutralization over an extended period of time.
- an improved antacid preparation is provided which increases both the degree and duration of action of the antacid and assures adequate antacid and antiulcer protection between doses.
- the preparation of this invention exerts antiulcer activity over twice as long as does the prior art antacid preparation.
- a still further advantage of the concentrated antacid composition of this invention is due to its high concentration. It eliminates the necessity of administering large daily volumes of antacid to obtain a therapeutic effect. The frequency of administration is greatly diminished when using the concentrated pharmaceutical composition of this invention.
- the novel pharmaceutical composition of this invention comprises an aqueous suspension comprising a high concentration of antacid and a combination of calcium phosphate monobasic and a pharmaceutically acceptable, nontoxic alkali earth or alkali metal gluconate especially sodium, potassium, magnesium or calcium gluconate.
- the aqueous suspension will comprise the antacid in combination with calcium phosphate monobasic and calcium gluconate. It has been unexpectedly discovered that the addition of calcium phosphate monobasic and at least one of the above-noted gluconate salts permit a much higher concentration of antacid in an aqueous suspension than has previously been possible.
- the monobasic calcium phosphate and the alkali gluconatc salt, preferably calcium gluconate will each be present in an amount of from about 0.5 percent to about 7.0 percent by weight/volume of the liquid suspension.
- the calcium phosphate monobasic and calcium gluconate will each be present in an amount of from about 2.0 percent to about 5.0 percent by weight/volume of the liquid suspension.
- the total concentration of the additives will be present in an amount of about 3 percent to about 10 percent.
- antacid ingredient is present up to about 50 percent weight/volume.
- antacid 50 present from about 25 percent to about 50 percent weight/volume, most advantageously from about 30 percent to about 45 percent weight/volume.
- concentrations of antacid can be used in the described vehicle of this invention if one desires a conventional antacid preparation of increased elegance.
- the antacid employed may be any of the conventional antacids well known to the art.
- the antacid may be calcium carbonate, magnesium oxide, magnesium trisilicatc. magnesium carbonate, aluminum hydroxide, bismuth subcarbonate, dihydroxy aluminum aminoacetate, bismuth aluminate, aluminum oxyhydroxide, sodium bicarbonate, magnesium hydroxide, sodium carbonate and aluminum phosphate or combinations thereof such as, for example, aluminum hydroxide-magnesium hydroxide glycine dried gel and aluminum hydroxide-magnesium carbonate codried gel.
- aqueous concentrated antacid suspensions are made following the techniques described hereafter. When are made following the techniques described hereafter.
- any desired pharmaceutically compatible adjuvant used in liquid preparations by those skilled in the art may be employed.
- preservatives such as methylparaben, or propylparaben
- flavoring agents such as oil of orange, lemon-lime flavors, raspberry flavor, cola flavors, mint flavors or the combination of these flavors or any solubilizing agent such as glycerin or propylene glycol
- antispasmodic agents, tranquilizers or other medicaments can be optionally included in the preparation.
- the cetyl dirnethyl benzyl ammonium chloride is dissolved in 65 ml. of water.
- the aluminum hydroxide, magnesium hydroxide and glycine are evenly suspended in the solution.
- the calcium gluconate and calcium phosphate monobasic are then added.
- the calcium carbonate, hydroxypropyl methylcellulose and antifoam are also added to the suspension with gently agitation.
- the flavor is added and the suspension is brought to the desired volume by the addition of sufficient water.
- EXAMPLE 2 Ingredients Amount Aluminum hydroxide, NF 22.70 gm Magnesium hydroxide. NF 13.28 gm. Precipitated calcium carbonate. USP 9.00 gm. Cetyl dirnethyl benzyl ammonium chloride 0.01 gm Calcium cyclamate 0.03 gm. Calcium phosphate monobasic 3.00 gm Calcium gluconate 3.00 gm. glycerin 10.50 ml. Lemon-lime flavor 0.01 ml. Water, USP qa ad 100.00 ml The cetyl dirnethyl benzyl ammonium chloride is dissolved in 65 ml. of water.
- the aluminum hydroxide and magnesium hydroxide are evenly suspended in the solution.
- the calcium gluconate and calcium phosphate monobasic are added with agitation, then the calcium carbonate, calcium cyclamate and glycerin are added to the suspension with gentle agitation.
- the flavor is then added and the suspension is brought to the desired volume by the addition of suflicient water.
- EXAMPLE 3 Ingredients Amount Aluminum hydroxide, NF 27.5 gm. Methylparaben 0.045 gm. Propylparaben 0.020 gm Propylene glycol 5.00 ml. Calcium phosphate monobasic 3.00 gm. Sodium gluconate 2.50 gm Imitation Wintergreen 0.25 ml. Purified water qs ad 100.00 ml.
- Aluminum hydroxide is evenly suspended in 65 ml. of water and the calcium phosphate monobasic and sodium gluconate are added.
- the parabens are dissolved in the propylene glycol with the aid of heat and added to the suspension.
- the flavor is then added and the suspension is brought to the desired volume by the addition of sufficient water.
- the cetyl dirnethyl benzyl ammonium chloride is dissolved in 65 m1. of water.
- the aluminum hydroxide and magnesium carbonate are evenly suspended in the solution.
- the magnesi um gluconate and calcium phosphate monobasic are added with agitation, then the hydroxypropyl methylcellulose and calcium cyclamate are added to the suspension with gentle agitation.
- the flavor is then added and the suspension is brought to the desired volume by the addition of sufficient water.
- a pharmaceutically elegant liquid pharmaceutical composition for oral use comprising from about 25 percent to about 50 percent of a solid antacid material comprising aluminum hydroxide, magnesium hydroxide, calcium carbonate, magnesium oxide, magnesium trisilicatc, magnesium carbonate, bismuth subcarbonate. dihydroxy aluminum aminoacetate, bismuth aluminate, aluminum oxyhydroxide. sodium bicarbonate, sodium carbonate, aluminum phosphate, glycine or combinations thereof suspended in an aqueous vehicle containing from about 0.5 percent to about 7.0 percent weight/volume of monobasic calcium phosphate and at least one of sodium, potassium, calcium or magnesium gluconates the total concentrations of phosphate and gluconate being from about 3 percent to about 10 percent.
- a solid antacid material comprising aluminum hydroxide, magnesium hydroxide, calcium carbonate, magnesium oxide, magnesium trisilicatc, magnesium carbonate, bismuth subcarbonate. dihydroxy aluminum aminoacetate, bismuth aluminate, aluminum oxyhydroxide. sodium bicarbonate, sodium
- composition of claim 1 wherein the gluconate salt is calcium gluconate.
- composition of claim 3 wherein the antacid is present from about 30 percent to about 45 percent weight/volume and the monobasic calcium phosphate and calcium gluconate are each present in an amount of from about 2.0 percent to about 5.0 percent.
- composition of claim 2 wherein the antacid is magnesium hydroxide, aluminum hydroxide, magnesium carbonate. calcium carbonate or combinations thereof.
- composition of claim 1 in which the antacid is at least one of aluminum hydroxide, magnesium carbonate or calcium carbonate.
- composition of claim 1 in which the essential ingredients in the aqueous vehicle comprise about 19 percent aluminum hydroxide, about 11 percent magnesium hydroxide, about 7.5 percent calcium carbonate, about 3.7percent calcium phosphate monobasic, and about 2 per- 5 cent calcium gluconate.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Pharmaceutically elegant aqueous pharmaceutical suspensions having antacid and antiulcer activity comprising a high concentration of antacid and a combination of calcium phosphate monobasic and a nontoxic alkali metal or alkaline earth gluconate salt such as sodium, potassium, calcium or magnesium gluconate.
Description
United States Patent David Mayron Whitpain Township;
Frank J. Tiano, Philadelphia, both of Pa. 7 19,234
Apr. 5, 1968 Nov. 16, 1971 Smith Kline 8: French Laboratories Philadelphia, Pa.
inventors App]. No. Filed Patented Assignee CONCENTRATED AQUEOUS LIQUID ANTACID COMPOSITIONS CONTAINING CERTAIN PHOSPHATE AND GLUCONATE SALTS 6 Claims, No Drawings US. Cl 424/128, 424/127, 424/131, 424/154, 424/155, 424/156, 424/157, 424/158, 424/180, 424/319 Int. Cl. A611: 27/00 Field ofSearch 424/128, 131,154,155,156,157,158,180,127,319
References Cited UNITED STATES PATENTS 3,062,714 1 1/1962 Pitkin et a1.... 424/128 3,215,601 11/1965 Stolar 424/128 3,361,769 1/1968 Halpem et a1. 424/180 OTHER REFERENCES Merck index, 5th Edition, 1940, page 109 Merck Index, 5th Edition, 1940, page 109 Primary Examiner-Albert T. Meyers Assistant Examiner-Daren M. Stephens Attorneys-William H. Edgerton, Richard D. Foggio, Joan S.
Keps, Arthur R. Eglington, Alan D. Lourie and Joseph A. Marlino CONCEN'IRA'I'ED AQUEOUS LIQUID AN'IACID COMPOSITIONS CONTAINING CERTAIN PHOSPHATE AND GLUCONATE SALTS This invention relates to new phannaceutically elegant antacid compositions. More specifically, this invention relates to aqueous pharmaceutical suspensions for oral use having antacid and antiulcer properties which contain a high concentration of antacid but which are also pharmaceutically stable and very palatable.
Therapeutically, antacids are used for the treatment of gastric hyperacidity, dyspepsia and peptic ulcers. Antacids have played a major role in the clinical management of peptic ulcers and in appropriate doses to relieve the plain of this condition.
One of the major disadvantages of using the currently available liquid antacid preparations for ulcer therapy is that they necessarily contain a low concentration, approximately 8 percent, of active antacid ingredient. These commercially available antacid preparations are rapidly and readily eliminated from the stomach as it empties. After a 30-minute period not enough antacid remains to provide effective antacid or antiulcer activity. In an attempt to overcome this short duration of action and to obtain a sustained protective efiect recent therapy comprises administering the prior art liquid antacid preparations at hourly intervals. Even when these are administered within these frequent hourly intervals the desired therapeutic effect, maintenance of gastric pH above 3.5, is frequently lost between doses. This procedure also makes it diflicult, if not impossible, to control the gastric acidity during the sleeping hours.
It is also apparent that because of the low concentration of current liquid antacid preparations this method of therapy, particularly for peptic ulcers, involves the oral administration of continuous and large daily volumes of antacid to keep the gastric contents neutralized. The administration of larger volumes of the commercial liquid antacid suspensions per does has proven very impractical. Most important, it has been demonstrated that increasing the volume of the suspension does not increase the duration of action and produces substantially the same therapeutic effect. Secondly, increasing the volume of antacid per dose would result in a serious personal discomfort and expense.
A further disadvantage is that even commercially available antacid products have well recognized stability problems. One of these is their tendency to coagulate and clump upon standing. Further, the palatability of the prior art liquid antacids is very objectionable, i.e. they have a chalky and astringent taste. These problems are multiplied as the concentration of antacid increase.
it is therefore the object of this invention to provide more concentrated forms of liquid antacid suspensions which are stable and palatable but still provide for prompt and long-acting antacid and antiulcer activity, i.e., antacid and ulcer protectionwell beyond the normal gastric emptying time and of suflicient duration of effective activity to maintain the gastric contents at a desirable pH between doses.
Unexpectedly the preparations of this invention offer a much more concentrated form of antacid preparation than has been previously available. if such a concentration could be prepared in the vehicle of the prior art antacid preparation it would resemble a slightly damp chalk powder. This invention therefore provides a more convenient, stable and palatable liquid for antacid therapy. The preparation in accordance with this invention can contain as high as 50 percent antacid which represents more than a fivefold increase in concentration over the commercially available liquid antacid preparations.
The novel phamtaceutical preparations of this invention are unique in that they are not only much more concentrated than the commercially available antacid preparations but are also more pharmaceutically elegant. These antacid suspensions are more stable and have improved palatability being free of the gritty, astringent, chalky taste-which is so prevalent even with the previously known antacid compositions.
The novel pharmaceutical compositions of this invention are also unique in that they provide for improved concentrated liquid antacid formulations of the type which promptly neutralize gastric acidity and maintain this neutralization over an extended period of time. In accordance with this invention, an improved antacid preparation is provided which increases both the degree and duration of action of the antacid and assures adequate antacid and antiulcer protection between doses. When equal volumes of a representative liquid antacid preparation of this invention and the leading commercial antacid preparation are administered orally in standard tests the preparation of this invention exerts antiulcer activity over twice as long as does the prior art antacid preparation.
A still further advantage of the concentrated antacid composition of this invention is due to its high concentration. It eliminates the necessity of administering large daily volumes of antacid to obtain a therapeutic effect. The frequency of administration is greatly diminished when using the concentrated pharmaceutical composition of this invention.
The novel pharmaceutical composition of this invention comprises an aqueous suspension comprising a high concentration of antacid and a combination of calcium phosphate monobasic and a pharmaceutically acceptable, nontoxic alkali earth or alkali metal gluconate especially sodium, potassium, magnesium or calcium gluconate. Most advantageously, the aqueous suspension will comprise the antacid in combination with calcium phosphate monobasic and calcium gluconate. It has been unexpectedly discovered that the addition of calcium phosphate monobasic and at least one of the above-noted gluconate salts permit a much higher concentration of antacid in an aqueous suspension than has previously been possible. The employment of the combination of these additives has the further added advantage in that it not only produces an aqueous suspension of an antacid having a high concentration but it also provides for a palatable and stable preparation. The presence of calcium phosphate monobasic and a gluconate salt in the aqueous vehicle efiectively prevents the suspended antacid from clumping or caking at the bottom of the container thus insuring proper dosage by simple shaking before use.
it has been discovered that these additives must be present in combination in order to achieve the advantages of stability and palatability noted above. Ifeither the monobasic calcium phosphate or one of the disclosed gluconate salts is employed alone to prepare a concentrated aqueous antacid suspension the resulting composition will slowly thicken, then solidify into a nonpourable mass. When these additives are used in combination the resulting concentrated antacid suspension results in the described pharmaceutically elegant preparation.
Advantageously, the monobasic calcium phosphate and the alkali gluconatc salt, preferably calcium gluconate, will each be present in an amount of from about 0.5 percent to about 7.0 percent by weight/volume of the liquid suspension. Most advantageously, the calcium phosphate monobasic and calcium gluconate will each be present in an amount of from about 2.0 percent to about 5.0 percent by weight/volume of the liquid suspension. The total concentration of the additives will be present in an amount of about 3 percent to about 10 percent.
By the term high concentration of antacid is meant that the antacid ingredient is present up to about 50 percent weight/volume. Preferably, the antacid 50 present from about 25 percent to about 50 percent weight/volume, most advantageously from about 30 percent to about 45 percent weight/volume. Of course, lower concentrations of antacid can be used in the described vehicle of this invention if one desires a conventional antacid preparation of increased elegance.
The antacid employed may be any of the conventional antacids well known to the art. For example, the antacid may be calcium carbonate, magnesium oxide, magnesium trisilicatc. magnesium carbonate, aluminum hydroxide, bismuth subcarbonate, dihydroxy aluminum aminoacetate, bismuth aluminate, aluminum oxyhydroxide, sodium bicarbonate, magnesium hydroxide, sodium carbonate and aluminum phosphate or combinations thereof such as, for example, aluminum hydroxide-magnesium hydroxide glycine dried gel and aluminum hydroxide-magnesium carbonate codried gel.
The above aqueous concentrated antacid suspensions are made following the techniques described hereafter. When are made following the techniques described hereafter. When necessary, any desired pharmaceutically compatible adjuvant used in liquid preparations by those skilled in the art may be employed. For example, preservatives such as methylparaben, or propylparaben, flavoring agents such as oil of orange, lemon-lime flavors, raspberry flavor, cola flavors, mint flavors or the combination of these flavors or any solubilizing agent such as glycerin or propylene glycol may be employed. Further, antispasmodic agents, tranquilizers or other medicaments can be optionally included in the preparation.
The invention will be further clarified by the following specific examples. These examples are not limiting but are used to make obvious to one skilled in the art the full practice of the method of this invention.
The cetyl dirnethyl benzyl ammonium chloride is dissolved in 65 ml. of water. The aluminum hydroxide, magnesium hydroxide and glycine are evenly suspended in the solution. The calcium gluconate and calcium phosphate monobasic are then added. The calcium carbonate, hydroxypropyl methylcellulose and antifoam are also added to the suspension with gently agitation. The flavor is added and the suspension is brought to the desired volume by the addition of sufficient water.
EXAMPLE 2 Ingredients Amount Aluminum hydroxide, NF 22.70 gm Magnesium hydroxide. NF 13.28 gm. Precipitated calcium carbonate. USP 9.00 gm. Cetyl dirnethyl benzyl ammonium chloride 0.01 gm Calcium cyclamate 0.03 gm. Calcium phosphate monobasic 3.00 gm Calcium gluconate 3.00 gm. glycerin 10.50 ml. Lemon-lime flavor 0.01 ml. Water, USP qa ad 100.00 ml The cetyl dirnethyl benzyl ammonium chloride is dissolved in 65 ml. of water. The aluminum hydroxide and magnesium hydroxide are evenly suspended in the solution. The calcium gluconate and calcium phosphate monobasic are added with agitation, then the calcium carbonate, calcium cyclamate and glycerin are added to the suspension with gentle agitation. The flavor is then added and the suspension is brought to the desired volume by the addition of suflicient water.
EXAMPLE 3 Ingredients Amount Aluminum hydroxide, NF 27.5 gm. Methylparaben 0.045 gm. Propylparaben 0.020 gm Propylene glycol 5.00 ml. Calcium phosphate monobasic 3.00 gm. Sodium gluconate 2.50 gm Imitation Wintergreen 0.25 ml. Purified water qs ad 100.00 ml.
Aluminum hydroxide is evenly suspended in 65 ml. of water and the calcium phosphate monobasic and sodium gluconate are added. The parabens are dissolved in the propylene glycol with the aid of heat and added to the suspension. The flavor is then added and the suspension is brought to the desired volume by the addition of sufficient water.
The cetyl dirnethyl benzyl ammonium chloride is dissolved in 65 m1. of water. The aluminum hydroxide and magnesium carbonate are evenly suspended in the solution. The magnesi um gluconate and calcium phosphate monobasic are added with agitation, then the hydroxypropyl methylcellulose and calcium cyclamate are added to the suspension with gentle agitation. The flavor is then added and the suspension is brought to the desired volume by the addition of sufficient water.
What is claimed is:
l. A pharmaceutically elegant liquid pharmaceutical composition for oral use comprising from about 25 percent to about 50 percent of a solid antacid material comprising aluminum hydroxide, magnesium hydroxide, calcium carbonate, magnesium oxide, magnesium trisilicatc, magnesium carbonate, bismuth subcarbonate. dihydroxy aluminum aminoacetate, bismuth aluminate, aluminum oxyhydroxide. sodium bicarbonate, sodium carbonate, aluminum phosphate, glycine or combinations thereof suspended in an aqueous vehicle containing from about 0.5 percent to about 7.0 percent weight/volume of monobasic calcium phosphate and at least one of sodium, potassium, calcium or magnesium gluconates the total concentrations of phosphate and gluconate being from about 3 percent to about 10 percent.
2. The pharmaceutical composition of claim 1 wherein the gluconate salt is calcium gluconate.
3. The pharmaceutical composition of claim 1 wherein the antacid is present from about 30 percent to about 45 percent weight/volume and the monobasic calcium phosphate and calcium gluconate are each present in an amount of from about 2.0 percent to about 5.0 percent.
4. The pharmaceutical composition of claim 2 wherein the antacid is magnesium hydroxide, aluminum hydroxide, magnesium carbonate. calcium carbonate or combinations thereof.
5. The pharmaceutical composition of claim 1 in which the antacid is at least one of aluminum hydroxide, magnesium carbonate or calcium carbonate.
6. The pharmaceutical composition of claim 1 in which the essential ingredients in the aqueous vehicle comprise about 19 percent aluminum hydroxide, about 11 percent magnesium hydroxide, about 7.5 percent calcium carbonate, about 3.7percent calcium phosphate monobasic, and about 2 per- 5 cent calcium gluconate.
i l 1 l
Claims (5)
- 2. The pharmaceutical composition of claim 1 wherein the gluconate salt is calcium gluconate.
- 3. The pharmaceutical composition of claim 1 wherein the antacid is present from about 30 percent to about 45 percent weight/volume and the monobasic calcium phosphate and calcium gluconate are each present in an amount of from about 2.0 percent to about 5.0 percent.
- 4. The pharMaceutical composition of claim 2 wherein the antacid is magnesium hydroxide, aluminum hydroxide, magnesium carbonate, calcium carbonate or combinations thereof.
- 5. The pharmaceutical composition of claim 1 in which the antacid is at least one of aluminum hydroxide, magnesium carbonate or calcium carbonate.
- 6. The pharmaceutical composition of claim 1 in which the essential ingredients in the aqueous vehicle comprise about 19 percent aluminum hydroxide, about 11 percent magnesium hydroxide, about 7.5 percent calcium carbonate, about 3.7percent calcium phosphate monobasic, and about 2 percent calcium gluconate.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71923468A | 1968-04-05 | 1968-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3621094A true US3621094A (en) | 1971-11-16 |
Family
ID=24889291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US719234A Expired - Lifetime US3621094A (en) | 1968-04-05 | 1968-04-05 | Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US3621094A (en) |
| AU (1) | AU443154B2 (en) |
| BE (1) | BE731060A (en) |
| DE (1) | DE1915798C3 (en) |
| FR (1) | FR2005599A1 (en) |
| GB (1) | GB1200157A (en) |
| IE (1) | IE33016B1 (en) |
| IL (1) | IL31858A (en) |
| LU (1) | LU58367A1 (en) |
| NL (1) | NL6905135A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4468381A (en) * | 1976-09-17 | 1984-08-28 | Norcliff Thayer, Inc. | Concentrated magnesium hydroxide preparations |
| EP0150115A2 (en) * | 1984-01-20 | 1985-07-31 | Webb-Waring Lung Institute | Solution for treating mammalian acidosis |
| WO1986005688A1 (en) * | 1985-03-27 | 1986-10-09 | Baxter Travenol Laboratories, Inc. | Supplemental calcium addition unit |
| US5455050A (en) * | 1993-11-12 | 1995-10-03 | Mcneil-Ppc, Inc. | Aqueous antacids with calcium carbonate and magnesium salt |
| US5498426A (en) * | 1994-10-03 | 1996-03-12 | The Procter & Gamble Company | Liquid antacid compositions |
| US5762962A (en) * | 1994-10-05 | 1998-06-09 | Warner-Lambert Company | Antacid pharmaceutical composition |
| US20060257358A1 (en) * | 2005-05-13 | 2006-11-16 | Depuy Products, Inc. | Suspension of calcium phosphate particulates for local delivery of therapeutic agents |
| US20090074889A1 (en) * | 2007-08-03 | 2009-03-19 | Ricardo Amador | Compositions and Methods for Treatment and Prevention of Osteoarthritis |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58192739U (en) * | 1982-06-19 | 1983-12-21 | 仁川 春夫 | Vehicle towing repair car |
| DE8334745U1 (en) * | 1983-12-03 | 1985-07-18 | Schöberl, Franz, 8400 Regensburg | Towing device for automobiles |
| AU590578B2 (en) * | 1985-04-18 | 1989-11-09 | Procter & Gamble Company, The | Treatment of non-ulcer dyspepsia with bismuth salts |
| WO1995010290A1 (en) * | 1993-10-13 | 1995-04-20 | Warner-Lambert Company | Antacid pharmaceutical composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3062714A (en) * | 1960-03-11 | 1962-11-06 | Lewis Howe Company | Antacid composition |
| US3215601A (en) * | 1963-02-07 | 1965-11-02 | Warner Lambert Pharmaceutical | Antacid composition and method of making same |
| US3361769A (en) * | 1964-01-22 | 1968-01-02 | Synergistics Inc | Bi-metallic salts of gluconic, glucuronic, or galacturonic acid |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3350266A (en) * | 1964-06-04 | 1967-10-31 | Bristol Myers Co | Antacid composition comprising aluminum hydroxide, magnesium hydroxide and magnesium gluconate |
-
1968
- 1968-04-05 US US719234A patent/US3621094A/en not_active Expired - Lifetime
-
1969
- 1969-03-19 AU AU52196/69A patent/AU443154B2/en not_active Expired
- 1969-03-20 IL IL31858A patent/IL31858A/en unknown
- 1969-03-21 IE IE374/69A patent/IE33016B1/en unknown
- 1969-03-27 DE DE1915798A patent/DE1915798C3/en not_active Expired
- 1969-03-31 FR FR6909622A patent/FR2005599A1/en active Granted
- 1969-04-01 GB GB17074/69A patent/GB1200157A/en not_active Expired
- 1969-04-02 NL NL6905135A patent/NL6905135A/xx unknown
- 1969-04-04 BE BE731060D patent/BE731060A/xx unknown
- 1969-04-04 LU LU58367D patent/LU58367A1/xx unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3062714A (en) * | 1960-03-11 | 1962-11-06 | Lewis Howe Company | Antacid composition |
| US3215601A (en) * | 1963-02-07 | 1965-11-02 | Warner Lambert Pharmaceutical | Antacid composition and method of making same |
| US3361769A (en) * | 1964-01-22 | 1968-01-02 | Synergistics Inc | Bi-metallic salts of gluconic, glucuronic, or galacturonic acid |
Non-Patent Citations (1)
| Title |
|---|
| Merck Index, 5th Edition, 1940, page 109 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4468381A (en) * | 1976-09-17 | 1984-08-28 | Norcliff Thayer, Inc. | Concentrated magnesium hydroxide preparations |
| EP0150115A2 (en) * | 1984-01-20 | 1985-07-31 | Webb-Waring Lung Institute | Solution for treating mammalian acidosis |
| EP0150115A3 (en) * | 1984-01-20 | 1985-08-07 | Webb-Waring Lung Institute | Solution for treating mammalian acidosis |
| WO1986005688A1 (en) * | 1985-03-27 | 1986-10-09 | Baxter Travenol Laboratories, Inc. | Supplemental calcium addition unit |
| US5455050A (en) * | 1993-11-12 | 1995-10-03 | Mcneil-Ppc, Inc. | Aqueous antacids with calcium carbonate and magnesium salt |
| US5631026A (en) * | 1993-11-12 | 1997-05-20 | Mcneil-Ppc, Inc. | Aqueous antacids with calcium carbonate and magnesium salt |
| US5498426A (en) * | 1994-10-03 | 1996-03-12 | The Procter & Gamble Company | Liquid antacid compositions |
| US5762962A (en) * | 1994-10-05 | 1998-06-09 | Warner-Lambert Company | Antacid pharmaceutical composition |
| US20060257358A1 (en) * | 2005-05-13 | 2006-11-16 | Depuy Products, Inc. | Suspension of calcium phosphate particulates for local delivery of therapeutic agents |
| US20090074889A1 (en) * | 2007-08-03 | 2009-03-19 | Ricardo Amador | Compositions and Methods for Treatment and Prevention of Osteoarthritis |
| US8790714B2 (en) * | 2007-08-03 | 2014-07-29 | Nucitec, S.A. De C.V. | Compositions and methods for treatment and prevention of osteoarthritis |
Also Published As
| Publication number | Publication date |
|---|---|
| LU58367A1 (en) | 1970-11-09 |
| DE1915798A1 (en) | 1969-11-06 |
| AU443154B2 (en) | 1973-11-28 |
| IE33016B1 (en) | 1974-02-20 |
| IE33016L (en) | 1969-10-05 |
| GB1200157A (en) | 1970-07-29 |
| NL6905135A (en) | 1969-10-07 |
| FR2005599A1 (en) | 1969-12-12 |
| DE1915798C3 (en) | 1978-04-27 |
| FR2005599B1 (en) | 1973-12-21 |
| IL31858A0 (en) | 1969-05-28 |
| BE731060A (en) | 1969-10-06 |
| DE1915798B2 (en) | 1977-08-25 |
| AU5219669A (en) | 1970-09-24 |
| IL31858A (en) | 1972-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3591680A (en) | Concentrated antacid compositions and method of producing antacid activity | |
| EP0183527B1 (en) | Absorbable calcitonin medicament | |
| US4885281A (en) | Sucralfate suspension | |
| US5102665A (en) | Pharmaceutical compositions | |
| US6828308B2 (en) | Compositions and methods for the treatment or prevention of inflammation | |
| US3621094A (en) | Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts | |
| DE69224684T2 (en) | Improved and dosed oral formulations of dideoxypurine nucleosides | |
| PT99143B (en) | A process for the preparation of a pharmaceutical composition in the form of a gel in a dispensing carton | |
| JP2711759B2 (en) | Antidiarrheal composition | |
| KR910005885B1 (en) | Solution containing lysozyme hydrochloride and dipotassium gly cyrrhizinate | |
| US4387093A (en) | Arthritis treatment | |
| US2477080A (en) | Antacid preparation | |
| RU2126249C1 (en) | Pharmaceutical composition for oral administration for treatment of patients with pathology of gastroenteric tract upper regions | |
| KR930701196A (en) | New treatment | |
| US4892877A (en) | Antitussive liquid compositions containing phenol | |
| US4190655A (en) | Amiloride citrate | |
| JPH07507293A (en) | Composition with histamine H↓2-receptor antagonist and cation exchanger complex | |
| JPH08295637A (en) | Local administrative agent for oral cavity | |
| IE914091A1 (en) | Novel treatment | |
| JPH0656677A (en) | Antacid composition | |
| Ivey et al. | Effect of carbenoxolone on the gastric mucosal barrier in man after administration of taurocholic acid | |
| US6075048A (en) | Pediatric method of use of bambuterol | |
| EP0030023A3 (en) | A heterocyclic compound and its synthesis, pharmaceutical formulations thereof and the use of the compounds and the formulations in medicine | |
| US3350266A (en) | Antacid composition comprising aluminum hydroxide, magnesium hydroxide and magnesium gluconate | |
| JPS62126130A (en) | Medicinal composition for animals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: SMITHKLINE BECKMAN CORPORATION, PENNSYLVANIA Free format text: CHANGE OF NAME;ASSIGNOR:SMITHKLINE CORPORATION;REEL/FRAME:004080/0769 Effective date: 19820304 Owner name: SMITHKLINE BECKMAN CORPORATION Free format text: CHANGE OF NAME;ASSIGNOR:SMITHKLINE CORPORATION;REEL/FRAME:004080/0769 Effective date: 19820304 |